Trends in Cardiovascular Medicine
Volume 16, Issue 6 , Pages 204-208 , August 2006

Cytochrome P450 Epoxygenase CYP2J2 and the Risk of Coronary Artery Disease

  • Martin Spiecker

      Affiliations

    • Department of Medicine II, St. Josef-Hospital Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    • ,
  • JamesK. Liao

      Affiliations

    • Vascular Medicine Research, Brigham and Women's Hospital, Cambridge, MA 02139, USA
    • Corresponding Author InformationAddress correspondence to: James K. Liao, Vascular Medicine Research, Brigham and Women's Hospital, 65 Landsdowne Street, Room 275, Cambridge, MA 02139, USA. Tel.: (+1) 617-768-8424; fax: (+1) 617-768-8425.

References 

  1. Abraham NG, Pinto A, Levere RD, Mullane K. Identification of heme oxygenase and cytochrome P-450 in the rabbit heart. J Mol Cell Cardiol. 1987;19:73–81
  2. Bauersachs J, Popp R, Hecker M, et al. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation. 1996;94:3341–3347
  3. Bauersachs J, Christ M, Ertl G, et al. Cytochrome P450 2C expression and EDHF-mediated relaxation in porcine coronary arteries is increased by cortisol. Cardiovasc Res. 2002;54:669–675
  4. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995;91:2488–2496
  5. Brand K, Page S, Rogler G, et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996;97:1715–1722
  6. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996;78:415–423
  7. Capdevila J, Chacos N, Werringloer J, et al. Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. Proc Natl Acad Sci U S A. 1981;78:5362–5366
  8. Capdevila JH, Karara A, Waxman DJ, et al. Cytochrome P-450 enzyme-specific control of the regio- and enantiofacial selectivity of the microsomal arachidonic acid epoxygenase. J Biol Chem. 1990;265:10865–10871
  9. Chen J, Capdevila JH, Zeldin DC, Rosenberg RL. Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol. 1999;55:288–295
  10. Collins T. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab Invest. 1993;68:499–508
  11. Cybulsky MI, Gimbrone MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991;251:788–791
  12. Daikh BE, Lasker JM, Raucy JL, Koop DR. Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J Pharmacol Exp Ther. 1994;271:1427–1433
  13. Fisslthaler B, Popp R, Kiss L, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 1999;401:493–497
  14. Fisslthaler B, Hinsch N, Chataigneau T, et al. Nifedipine increases cytochrome P4502C expression and endothelium-derived hyperpolarizing factor-mediated responses in coronary arteries. Hypertension. 2000;36:270–275
  15. Fisslthaler B, Michaelis UR, Randriamboavonjy V, et al. Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression. Biochim Biophys Acta. 2003;1619:332–339
  16. Fleming I, Michaelis UR, Bredenkotter D, et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res. 2001;88:44–51
  17. Guengerich FP, Mason PS. Immunological comparison of hepatic and extrahepatic cytochromes P-450. Mol Pharmacol. 1979;15:154–164
  18. Keeney DS, Skinner C, Wei S, et al. A keratinocyte-specific epoxygenase, CYP2B12, metabolizes arachidonic acid with unusual selectivity, producing a single major epoxyeicosatrienoic acid. J Biol Chem. 1998;273:9279–9284
  19. King LM, Ma J, Srettabunjong S, et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol. 2002;61:840–852
  20. Laethem RM, Koop DR. Identification of rabbit cytochromes P450 2C1 and 2C2 as arachidonic acid epoxygenases. Mol Pharmacol. 1992;42:958–963
  21. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844–2850
  22. Nguyen X, Wang MH, Reddy KM, et al. Kinetic profile of the rat CYP4A isoforms arachidonic acid metabolism and isoform-specific inhibitors. Am J Physiol. 1999;276:R1691–R1700
  23. Nishikawa Y, Stepp DW, Chilian WM. Nitric oxide exerts feedback inhibition on EDHF-induced coronary arteriolar dilation in vivo. Am J Physiol Heart Circ Physiol. 2000;279:H459–H465
  24. Nithipatikom K, Moore JM, Isbell MA, et al. Epoxyeicosatrienoic acids (EETs) in cardioprotection ischemic versus reperfusion injury. Am J Physiol Heart Circ Physiol. 2006;(in press)
  25. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285:1276–1279
  26. Node K, Ruan XL, Dai J, et al. Activation of Gαs mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem. 2001;276:15983–15989
  27. Oltman CL, Weintraub NL, VanRollins M, Dellsperger KC. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res. 1998;83:932–939
  28. Reuter H. Calcium channel modulation by neurotransmitters, enzymes and drugs. Nature. 1983;301:569–574
  29. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  30. Rifkind AB, Lee C, Chang TK, Waxman DJ. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch Biochem Biophys. 1995;320:380–389
  31. Ross R, Harker L. Hyperlipidemia and atherosclerosis. Science. 1976;193:1094–1100
  32. Seubert J, Yang B, Alyce Bradbury J, et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res. 2004;
  33. Spiecker M, Darius H, H T, et al. Risk of coronary artery disease associated with polymorphism of a cytochrome P450 epoxygenase, CYP2J2. Circulation. 2004;110:2132–2136
  34. Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys. 2005;433:413–420
  35. Stegeman JJ, Woodin BR, Klotz AV, et al. Cytochrome P-450 and monooxygenase activity in cardiac microsomes from the fish stenotomus chrysops. Mol Pharmacol. 1982;21:517–526
  36. Sun J, Sui X, Bradbury JA, et al. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res. 2002;90:1020–1027
  37. Thompson CM, Capdevila JH, Strobel HW. Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid. J Pharmacol Exp Ther. 2000;294:1120–1130
  38. Wang Y, Wei X, Xiao X, et al. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther. 2005;314:522–532
  39. Wu S, Moomaw CR, Tomer KB, et al. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem. 1996;271:3460–3468
  40. Wu S, Chen W, Murphy E, et al. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem. 1997;272:12551–12559
  41. Xiao YF, Ke Q, Seubert JM, et al. Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2. Mol Pharmacol. 2004;66:1607–1616
  42. Yang B, Graham L, Dikalov S, et al. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol. 2001;60:310–320
  43. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem. 2001;276:36059–36062
  44. Zeldin DC, DuBois RN, Falck JR, Capdevila JH. Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys. 1995;322:76–86

PII: S1050-1738(06)00066-1

doi: 10.1016/j.tcm.2006.04.001

Trends in Cardiovascular Medicine
Volume 16, Issue 6 , Pages 204-208 , August 2006

Article Tools

* Image Usage & Resolution